Evidence map›Paper›PMID 27340920›Full record

ArticleOncotarget2016

Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers.

Jayant K Rane, Holger H H Erb, Giovanna Nappo, Vincent M Mann, Matthew S Simms, Anne T Collins, Tapio Visakorpi, Norman J Maitland

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Expression of microRNA-99a-3p in Prostate Cancer Based on Bioinformatics Data and Meta-Analysis of a Literature Review of 965 Cases.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Pooled it
  2. SMARCD1 and Its Functional Relevance in SWI/SNF and Cancer.International journal of molecular sciences · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 3 countries.

Jayant K RaneThe Cancer Research Unit, Department of Biology, University of York, York, North Yorkshire, YO10 5DD, UK.
Holger H H ErbThe Cancer Research Unit, Department of Biology, University of York, York, North Yorkshire, YO10 5DD, UK.
Giovanna NappoThe Cancer Research Unit, Department of Biology, University of York, York, North Yorkshire, YO10 5DD, UK.
Vincent M MannHull York Medical School, University of Hull, Hull, East Yorkshire, HU6 7RX, UK.
Matthew S SimmsHull York Medical School, University of Hull, Hull, East Yorkshire, HU6 7RX, UK.
Anne T CollinsThe Cancer Research Unit, Department of Biology, University of York, York, North Yorkshire, YO10 5DD, UK.
Tapio VisakorpiProstate Cancer Research Center, Institute of Biosciences and Medical Technology - BioMediTech, University of Tampere and Tampere University Hospital, Tampere, 33520 Finland.
Norman J MaitlandThe Cancer Research Unit, Department of Biology, University of York, York, North Yorkshire, YO10 5DD, UK.
Castle Hill Hospital · GBHull York Medical School · GBKing's College London · GBMagna Graecia University · ITTampere University Hospital · FIUniversity of York · GBYorkshire Cancer Research · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiation therapy is a major primary treatment option for both localized early stage prostate cancer, and for advanced, regionally un-resectable, cancer. However, around 30% of patients still experience biochemical recurrence after radiation therapy within 10 years. Thus, identification of better biomarkers and new targets are urgently required to improve current therapeutic strategies. The miR-99 family has been shown to play an important role in the regulation of the DNA damage response, via targeting of the SWI/SNF chromatin remodeling factors, SMARCA5 and SMARCD1 in cell line models. In the present study, we have demonstrated that low expression of miR-99a and miR-100 is present in cell populations which are relatively radiation insensitive, for example in prostate cancer stem cells and in castration-resistant prostate cancer. Additionally, treatment of cells with the synthetic glucocorticoid, Dexamethasone resulted in decreased miR-99a and 100 expression, suggesting a new mechanism of miR-99a and 100 regulation in androgen-independent prostate cells. Strikingly, treatment of prostate cells with the glucocorticoid receptor inhibitor, Mifepristone was found to sensitize prostate cells to radiation by increasing the levels of miR-99a and miR-100. These results qualify the miR99 family as markers of radiation sensitivity and as potential therapeutic targets to improve efficiency of radiotherapy.

Indexed as

Cell Line, TumorDexamethasoneGene Expression Regulation, NeoplasticGlucocorticoidsHormone AntagonistsHumansMaleMicroRNAsMifepristoneNeoplastic Stem CellsProstatic NeoplasmsRadiation ToleranceReceptors, GlucocorticoidDexamethasoneGlucocorticoidsHormone AntagonistsMicroRNAsMifepristoneMIRN100 microRNA, humanMIRN99 microRNA, humanReceptors, Glucocorticoidcancer stem cellsDNA damage repairmifepristonemiRNAradiotherapy

Identifiers

PMID27340920
PMCPMC5239528
OpenAlexW2470595324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.